Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Auteurs principaux: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Elsevier
2019
|
Documents similaires
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
par: Theodora Markati, et autres
Publié: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
par: Marshall W. Hogarth, et autres
Publié: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
par: Fatima Amor, et autres
Publié: (2021-06-01) -
Genetic modifiers of respiratory function in Duchenne muscular dystrophy
par: Luca Bello, et autres
Publié: (2020-05-01) -
Duchenne Muscular Dystrophy
par: J Gordon Millichap
Publié: (1989-05-01)